SCHEMBL6281174

SCHEMBL6281174

CCOC(=O)c1cn(-c2ccccc2)c2occc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.49
TDP1 Q9NUW8 1/20 0.46
MAPT P10636 2/20 0.45
PIM1 P11309 1/20 0.45
IRAK1 P51617 1/20 0.45
CAMK2B Q13554 1/20 0.45
CAMK2G Q13555 1/20 0.45
CAMK2D Q13557 1/20 0.45
PIM3 Q86V86 1/20 0.45
GABRA2 P47869 2/20 0.44
GABRB2 P47870 2/20 0.44
LMNA P02545 3/20 0.43
TSHR P16473 1/20 0.43
CLEC4M Q9H2X3 1/20 0.43
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 4/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 1/20 0.42
KDM4E B2RXH2 3/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6281585 0.83 HPGD (0.47) MAOBTDP1MAPTPIM1IRAK1
SCHEMBL6281429 0.81 MAOB (0.48) MAOBTDP1MAPTGABRB2LMNA
SCHEMBL6284441 0.80 LMNA (0.56) MAOBTDP1MAPTLMNATSHR
SCHEMBL5101006 0.80 NR4A2 (0.59) MAOBTDP1MAPTPIM1IRAK1
SCHEMBL6282519 0.80 TSHR (0.48) MAOBTDP1MAPTGABRB2LMNA
SCHEMBL6282379 0.78 LMNA (0.48) MAOBTDP1MAPTLMNATSHR
SCHEMBL7128069 0.77 PIM1 (0.56) MAOBTDP1MAPTPIM1IRAK1
SCHEMBL6285810 0.76 ADRB2 (0.45) MAOBTDP1MAPTLMNATSHR
SCHEMBL10472497 0.75 KMT2A (0.59) TDP1MAPTPIM1IRAK1CAMK2B
SCHEMBL30417213 0.75 KMT2A (0.59) TDP1MAPTPIM1IRAK1CAMK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6878705-B2 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents PFIZER (US) 2005-04-12 US disclosed
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY 2004-12-23 US disclosed
EP-1465895-A2 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-10-13 EP disclosed
WO-2003059911-A2 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS IL4, ZC3HAV1, IRF3 MAOB 3232/4885TDP1 1612/4885MAPT 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.